Data from the phase 2 UCLA/TRIO-US L-07 trial presented at 2022 WCLC revealed that efficacy with talazoparib plus temozolomide improves upon historical controls in patients with extensive-stage small cell lung cancer.
Response rates with temozolomide plus nivolumab in extensive-stage small cell lung cancer show promise.
EGFR C797X mutations identified as leading cause of acquired resistance to osimertinib, according to real-world data from 2022 WCLC.
According to data from the phase 1 CHRYSALIS-2 trial that were presented at 2022 WCLC, a combination containing amivantamab, lazertinib, and chemotherapy was effective in patients with pretreated non–small cell lung cancer harboring EGFR mutations.
The phase 3 POSEIDON trial showed superior overall survival in patients with PD-L1–negative metastatic non–small cell lung cancer who were given durvalumab and chemotherapy plus tremelimumab.
The novel KRAS G12C inhibitor GDC-6036 induced a high response rate in patients with previously treated KRAS G12C mutation–positive non–small cell lung cancer.
Data from the phase 2 NADIM II trial appear to reinforce the superiority of nivolumab and chemotherapy vs chemotherapy alone after the regimen significantly improved overall survival progression-free survival, and pathologic complete response in patients with stage IIIA/B non–small cell lung cancer, according to investigators.
Data indicate that atezolizumab may achieve overall survival benefit compared with best supportive care in resected non–small cell lung cancer.
Following data presented from the phase 1/2 CodeBreak 100 and CodeBreak 101 trials, a regimen consisting of sotorasib with a safety lead-in followed by concurrent pembrolizumab will be further explored in patients with KRAS G12C–mutant non–small cell lung cancer.
Patients with treatment-naïve metastatic non–small cell lung cancer who received either sintilimab or pembrolizumab monotherapy, or either agent combined with chemotherapy, experienced comparable outcomes.